Skip to main content
Gland Pharma Limited logo

Gland Pharma Limited — Investor Relations & Filings

Ticker · GLAND ISIN · INE068V01023 LEI · 335800JJVDY5R6KF5K34 BSE.NS Manufacturing
Open in API
Filings indexed 678 across all filing types
Latest filing 2023-10-10 Share Issue/Capital Cha…
Country IN India
Listing BSE.NS GLAND

About Gland Pharma Limited

https://glandpharma.com

Gland Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) focused on injectable formulations. The company operates primarily through a business-to-business (B2B) model, providing development and manufacturing services for a diverse range of sterile injectables. Its portfolio encompasses complex generics across various therapeutic areas, including oncology, ophthalmology, anti-infectives, and orthopedics. Gland Pharma maintains a vertically integrated supply chain, ensuring control over critical raw materials and active pharmaceutical ingredients. The company serves a global market, with a significant presence in regulated regions such as the United States, Europe, Canada, and Australia. Its manufacturing facilities adhere to international quality standards and hold approvals from major regulatory bodies. Key strengths include expertise in niche segments like heparin and enoxaparin, alongside a robust pipeline of complex delivery systems.

Recent filings

Filing Released Lang Actions
ESOP/ESOS/ESPS
Share Issue/Capital Change Classification · 100% confidence The document is a notification addressed to stock exchanges about the allotment of equity shares due to the exercise of Employee Stock Options (ESOP). It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulation 30, which pertains to disclosure of material events. The content is an announcement of a capital change (allotment of shares) rather than a full financial report or detailed analysis. The document length is short (1452 characters), and it does not contain financial statements or detailed financial data. Therefore, it fits the category of Share Issue/Capital Change (SHA).
2023-10-10 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a notification about the closure of the trading window due to upcoming unaudited financial results for the quarter and half-year ending September 30, 2023. It references the SEBI (Prohibition of Insider Trading) Regulations, 2015, and informs stock exchanges about the trading restrictions. The document does not contain any financial data or results itself, nor does it include the actual financial report. It is a regulatory announcement related to insider trading compliance ahead of financial results disclosure. Given the short length (1500 characters) and the nature of the content, this is not a financial report but a regulatory filing informing about trading restrictions. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-09-29 English
Updates
Regulatory Filings Classification · 95% confidence The document is a short letter addressed to stock exchanges informing about the conclusion of a US FDA inspection at the company's manufacturing facility. It references a prior letter and provides an update on regulatory inspection status. There are no financial statements, no detailed financial data, no earnings information, no management discussion, or any other report content. The document is an announcement of a regulatory event related to compliance and inspection results. It is brief (1439 characters) and serves as a notification to the market rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-09-26 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice dated September 25, 2023, addressed to stock exchanges regarding the schedule of an Analyst/Institutional Investor Meeting. It is an announcement of a meeting schedule, not a report or transcript of the meeting itself. The document is only 1535 characters long and does not contain any financial data, results, or detailed presentation content. It fits the category of an Investor Presentation announcement or meeting schedule notice. However, since it only announces the schedule of the meeting and does not provide the presentation or transcript, it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about an upcoming investor meeting, not the meeting content itself.
2023-09-25 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice dated September 20, 2023, addressed to stock exchanges regarding the schedule of an Analyst/Institutional Investor Meeting. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, which governs disclosure of material events. The content is an announcement of a meeting schedule, not a report or transcript of the meeting itself. The document length is only 1553 characters, indicating it is a brief announcement rather than a detailed report or transcript. Therefore, it fits the category of an Investor Presentation announcement or meeting schedule notice. However, since it is only the schedule notice and not the presentation itself, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and disclosures that do not fit other categories.
2023-09-20 English
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation Classification · 90% confidence The document is a letter addressed to stock exchanges informing them about the schedule of analyst and institutional investor meetings. It references Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The content is about notifying the schedule of investor meetings, not the actual investor presentation or financial report. The document length is 3628 characters, which is relatively short and primarily serves as an announcement. There is no financial data, analysis, or detailed presentation content included. Therefore, this document is best classified as an Investor Presentation (IP) related announcement or notification of meetings with investors, but since it does not contain the presentation itself, it is not a full investor presentation report. However, given the options, the closest and most appropriate classification is Investor Presentation (IP) because it relates to investor meetings and presentations, rather than a regulatory filing or report publication announcement. Confidence is high due to clear context and content type.
2023-09-20 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.